* CNS Pharmaceuticals director Michal Fisher filed an initial Form 3 disclosure dated May 4, 2026.
Back to newsCNS Pharmaceuticals director Michal Fisher files initial beneficial ownership statementCCNSP•2026-08-18Initial Form 3 filing CNS Pharmaceuticals director Michal Fisher filed an initial Form 3 disclosure dated May 4, 2026. Related NewsDDaré Bioscience DARE-HPV program advances with non-dilutive US government fundingDARE•2026-08-18SU.S. July industrial output rises 0.2 percentSPY•2026-08-18AAcuity Inc. Names Ruth Gratzke President Of Acuity Brands LightingAYI•2026-08-18SourcesSSCNS Pharmaceuticals director Michal Fisher files initial beneficial ownership statementSec
CNSP•CNSP•CNSP•CNSP•
